Antilipemic agents are drug classes that lower circulating cholesterol and triglycerides by intervening at distinct points in lipid handling — endogenous synthesis, intestinal absorption, enterohepatic bile acid recirculation, and lipoprotein production — with each mechanism predicting the class's lipid-fraction effect and its characteristic toxicity. Because most of these pathways converge on hepatic lipid metabolism and skeletal muscle energy handling, hepatotoxicity and myopathy recur as a cross-class adverse-effect signature, making liver enzyme and creatine kinase surveillance the shared monitoring principle rather than a class-specific one. The topic belongs to cardiovascular pharmacology within nursing pharmacotherapeutics and connects lipid biochemistry to atherosclerotic risk reduction, exemplifying the parent discipline's rule that mechanism of action determines both indication and required monitoring.
Antilipemic agents are drug classes that lower circulating cholesterol and triglycerides by intervening at distinct points in lipid handling — endogenous synthesis, intestinal absorption, enterohepat…